The prognostic value of p53 and c-erb b-2 immunostaining is overrated for patients with lymph node negative breast carcinoma
Open Access
- 15 February 2000
- Vol. 88 (4) , 804-813
- https://doi.org/10.1002/(sici)1097-0142(20000215)88:4<804::aid-cncr11>3.0.co;2-y
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- p53 as a prognostic factor in stage I breast cancerBritish Journal of Cancer, 1995
- Prognostic significance of c-erbB-2 expression in node negative breast cancerBritish Journal of Cancer, 1993
- Immunohistochemical analysis of p53 and HER-2/neu proteins in human tumors.Journal of Histochemistry & Cytochemistry, 1991
- The long term prognostic significance of c-erbB-2 in primary breast cancerBritish Journal of Cancer, 1991
- c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodesBritish Journal of Cancer, 1991
- Adjuvant Immunotherapy in Node-Negative Patients: Results of a Scandinavian StudyPublished by Springer Nature ,1989
- Immunohistochemical distribution of c‐erbB‐2 in infiltrating and in situ breast cancerInternational Journal of Cancer, 1988
- Semiquantitative oestrogen receptor assay in formalin-fixed paraffin sections of human breast cancer tissue using monoclonal antibodiesBritish Journal of Cancer, 1986
- Postoperative radiotherapy in breast cancer—long-term results from the Oslo studyInternational Journal of Radiation Oncology*Biology*Physics, 1986
- Histological Grading and Prognosis in Breast CancerBritish Journal of Cancer, 1957